

MEDTRONIC CONFIDENTIAL

Special 510(k) Premarket Notification  
Model 6495 Bipolar Temporary Myocardial Pacing Lead  
Attachment D: 510(k) Summary of Substantial Equivalence

AUG 14 2001

# ATTACHMENT D 510(K) SUMMARY OF SUBSTANTIAL EQUIVALENCE

## Submitter

---

Medtronic, Inc.  
7000 Central Avenue N.E.  
Minneapolis, MN 55432

Contact: Tina Benoit, Associate Product Regulation Manager  
Telephone: (763) 514-4112  
Fax: (763) 514-6424  
E-Mail: [tina.benoit@medtronic.com](mailto:tina.benoit@medtronic.com)

Date Prepared: July 31, 2001

## Name of Device

---

Trade Name: Temporary Pacemaker Electrode, 74 LDF

Common Name: Temporary Pacing Lead

Classification: Class II

## **Predicate Devices**

---

The predicate device for the Model 6495 Bipolar Temporary Myocardial Pacing Lead is the currently market released Model 6495 Bipolar Temporary Myocardial Pacing Lead.

## **Device Description**

---

The Model 6495 Bipolar Temporary Myocardial Pacing Lead consists of an insulated multi-filament lead, which contains a distal, discrete, ring electrode, a discrete, tip electrode, and a coaxial conductor lead body. Each discrete electrode is crimped onto a conductor and terminates in an atraumatic myocardial curved needle. A blue monofilament coil provides fixation while the lead is implanted in myocardial tissue. An atraumatic chest needle at the proximal end of the conductor wire permits exiting the pacing lead through the chest wall. Terminated on the back of the chest needle are two breakaway connector pins. To remove the pacing lead, gentle traction should be applied. No part of the lead remains in the body.

## **Packaging**

---

The sterile packaging for the Model 6495 Bipolar Temporary Myocardial Pacing Lead consists of a double pouch configuration. The inner pouch (or package liner) and outer pouch materials are transparent Tyvek - polyester/polyethylene laminate. The pouches are heat-sealed.

## **Intended Use**

---

The Model 6495 Bipolar Temporary Myocardial Pacing Lead is designed for temporary atrial and ventricular pacing and sensing for a contemplated implant duration of 7 day or less. The device is supplied sterile and intended for single use only.

## **Technological Characteristics**

---

The technology used with the Model 6495 Bipolar Temporary Myocardial Pacing Lead is the same technological characteristics as the predicate device.

## Summary of Studies

---

Medtronic, Inc. performed system compatibility testing to support that the Model 6495 Bipolar Temporary Myocardial Pacing lead is equivalent to the predicate device. Device testing included:

- Environmental Conditioning
- Visual Verification
- Dimensional Testing
- Electrical Testing
- Mechanical Testing

All system compatibility tests performed have demonstrated that the modified Model 6495 heartwire meets the specified requirements.

## Sterilization Validation

---

The Model 6495 Bipolar Temporary Myocardial Pacing Lead is sterilized using a 100% Ethylene Oxide (ETO) sterilization process. Processes appropriate for sterilizing the devices were validated.

## Conclusion

---

Through data and information presented, numerous similarities support a determination of substantial equivalence and show the device modifications do not affect the intended use of the device or alter the fundamental scientific technology of the device. Market clearance of the Model 6495 Bipolar Temporary Myocardial Pacing Lead is supported through this Special 510(k) Premarket Notification.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

AUG 1 4 2001

Ms. Tina L. Benoit  
Medtronic, Inc.  
Cardiac Rhythm Management  
7000 Central Avenue NE  
Minneapolis, MN 55432-3576

Re: K012460

Trade Name: Model 6495 Bipolar Temporary Myocardial Pacing Lead  
Regulation Number: 21 CFR 870.3680  
Regulatory Class: Class II (two)  
Product Code: 74 LDF  
Dated: July 31, 2001  
Received: August 1, 2001

Dear Ms. Benoit:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this

response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

  
James E. Dillard III  
Director  
Division of Cardiovascular  
and Respiratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

# INDICATIONS FOR USE

510(k) Number (if known): N/A K012460

Device Name: Medtronic® Model 6495 Bipolar Temporary Myocardial Pacing Lead

Indications For Use: The Model 6495 Bipolar Temporary Myocardial Pacing Lead is designed for temporary atrial and ventricular pacing and sensing for a contemplated implant duration of 7 days or less. The device is supplied sterile and intended for single use only.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒                       
(Per 21 CFR 801.109)

OR

Over-The-Counter Use                     

*Robert T. Hill*  
Division of Cardiovascular & Respiratory Devices  
510(k) Number K012460

(Optional Format 1-2-96)